Selecting Safe Chemotherapy Regimens in Older Breast Cancer Patients

Video

This video reviews the evidence for safe and effective chemotherapy regimens in older patients with breast cancer and highlights the need for geriatric assessment in this population.

In breast cancer trials, most chemotherapy regimens are studied in younger, healthier patients. In practice, many of these regimens have been shown to be too toxic for older women, with higher rates of hospitalization among these patients.

In this video, Hans Wildiers, MD, PhD, of University Hospitals Leuven in Belgium, reviews some of the regimens that are too toxic, highlights one regimen shown to be feasible, and discusses the need for geriatric assessment in this population.  

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content